Iambic Therapeutics
iambic.ai
Oncology Therapeutics
Drug Discovery
Drug Discovery AI
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$1.3M
8 rounds on record
Latest round
$75k
Convertible Note · Sep 2024 · 2 yr ago
Grants
$1.2M
2 grants · CORDIS
Backers
5
Coatue, Illumina Ventures
The money's age
Long since its last round
25 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 15, 2024
Won a grant $991k · CORDIS
Mar 4, 2024
Raised a round Venture round $120k · SEC Form D
Jul 17, 2023
Raised a round Convertible Note $30k · SEC Form D
May 6, 2022
Raised a round Convertible Note $130k · SEC Form D
Sep 1, 2021
Won a grant $256k · CORDIS
Mar 3, 2021
Raised a round Venture round $698k · SEC Form D
Feb 7, 2021
Raised a round Venture round $224k · SEC Form D
2019
Founded
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | Sep 2024 | $75k | — | SEC Form D |
| Grant | Jul 2024 | $991k | — | CORDIS |
| Venture round | Mar 2024 | $120k | — | SEC Form D |
| Convertible Note | Jul 2023 | $30k | — | SEC Form D |
| Convertible Note | May 2022 | $130k | — | SEC Form D |
| Grant | Sep 2021 | $256k | — | CORDIS |
| Venture round | Mar 2021 | $698k | — | SEC Form D |
| Venture round | Feb 2021 | $224k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Iambic Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Maeve WangExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Coatue 
Nexus Venture Partners 
OrbiMed 
Sequoia Capital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Genesis Molecular AI is a drug discovery company headquartered in Burlingame, California, and founded in 2019. The company combines deep…
Iambic Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California, that uses physics-informed artificial…
Xaira Therapeutics uses generative models for protein design and drug discovery. It launched with one of the largest initial funding rounds…
Terray Therapeutics is a venture-backed biotechnology company that combines nanotechnology, experimental science, machine learning and…
Light Horse is a small molecule drug discovery company that is leading the way in a.
Avicenna Biosciences is a drug development company using machine learning-enhanced medicinal chemistry to accelerate the lead-to-candidate…
News
Upcoming To be released on October 30, 2025 October 30, 2025 2025 Promise & Reality: Decoding AI's Impact On Drug Development Learn more
Read more
Report
Upcoming To be released on September 23, 2025 September 23, 2025 2025 Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development Learn more
Read more
Report
Upcoming To be released on September 22, 2025 September 22, 2025 2025 Leveraging AIML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance Learn more
Read more
Report
Upcoming To be released on September 10, 2025 September 10, 2025 2025 Predictive Drug Discovery with Enchant v2 Learn more
Read more
Report
Upcoming To be released on August 18, 2025 August 18, 2025 2025 Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at WCLC25 Learn more
Read more
Report
Upcoming To be released on August 6, 2025 August 6, 2025 2025 Video: Iambic CEO Tom Miller Interview at the NASDAQ MarketSite Learn more
Read more
Report
Upcoming To be released on August 1, 2025 August 1, 2025 2025 Presentation and poster shared at the Gordon Research Conference: High Throughput Chemistry and Chemical Biology Learn more
Read more
Report
Upcoming To be released on July 29, 2025 July 29, 2025 2025 Video: Iambic Therapeutics CEO Tom Miller on NYSE Floor Talk Learn more
Read more
Report
Upcoming To be released on July 24, 2024 July 24, 2024 2024 Multi-Modal and Multi-Task Transformer for Small Molecule Drug Discovery Learn more
Read more
Report
Upcoming To be released on February 23, 2024 February 23, 2024 2024 Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures Learn more
Read more
Report
People
Maeve Wang
Executive Officer, Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Diego
United States
HQ
Financials
Total raised
$2.5M
Latest round
Convertible Note
Funding rounds
8
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Convertible Note | 2024 | $75k | Details |
| Grant | 2024 | $991k | Details |
| Venture - Series Unknown | 2024 | $120k | Details |
| Convertible Note | 2023 | $30k | Details |
| Convertible Note | 2022 | $130k | Details |
| Grant | 2021 | $256k | Details |
| Venture - Series Unknown | 2021 | $698k | Details |
| Venture - Series Unknown | 2021 | $224k | Details |